Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells

Biochemical Pharmacology

Volumn 51, Issue 12, 1996, Pages 1649-1659

  Grem, Jean L ^a,b   Politi, Pedro M ^a,c   Berg, Stacey L ^a,d   Benchekroun, Nabil M ^a   Patel, Mahendra ^a   Balis, Frank M ^a   Sinha, Birandra K ^a   Dahut, William ^a   Allegra, Carmen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL NAVAL MEDICAL CENTER   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DNA binding; DNA fragmentation; DNA intercalation; pyrazoloacridine

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL LEVEL; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RNA SYNTHESIS;

EID: 0029938510     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00130-X     Document Type: Article

References (36)

1. Jackson RC, Sebolt JS, Shilis JL and Leopold WR, The pyrazoloacridines: Approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8: 39-47, 1990.
2. LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME and Corbett TH, Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50: 4900-4905, 1990.
3. Sebolt JS, Scavone SV, Pinter CD, Hamelehle KL, Von Hoff DD and Jackson R, Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299-4304, 1987.
4. Sebolt J, Havlick M, Hamelehle K, Nelson J and Jackson R, Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24: 219-224, 1989.
5. Sebolt-Leopold JS and Scavone SV, Biochemistry of the interactions between DNA and the pyrazoloacridines, a series of biologically novel anticancer agents. Proc Am Assoc Cancer Res 32: 334, 1991.
6. Rowe TC, Chen GL, Hsiang YH and Liu LF, DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46: 2021-2026, 1986.
7. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
8. Politi PM and Sinha BK, Role of drug uptake, efflux and binding of etoposide in sensitive and resistant human tumor cell lines: Implications for the mechanisms of drug resistance. Mol Pharmacol 35: 271-278, 1989.
9. Berg SL, Balis FM, McCully CL, Godwin KS and Poplack DG, Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 51: 5467-5470, 1991.
10. Grem JL and Allegra CJ, Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and cytosine arabinoside by cyclopentenyl cytosine. Cancer Res 50: 7279-7284, 1990.
11. Sherman PA and Fyfe JA, Enzyme assay for deoxyribonucleotide triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 180: 222-226, 1989.
12. Kohn KW, Ewig RAC, Erickson LC and Zwelling LA, Measurement of strand breaks and cross-links by alkaline elution. In: DNA Repair. A Laboratory Manual of Research Procedures (Eds. Friedberg EC and Hanawalt PC), pp. 379-401. Marcel Dekker, New York, 1981.
13. Grem JL, Geoffroy F, Politi PM, Cuddy DP, Ross DD, Nguyen D, Steinberg SM and Allegra CJ, Determinants of sensitivity to 1-β-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells. Mol Pharmacol 48: 305-315, 1995.
14. Bertrand R, Sarang M, Jenkin J, Kerrigan D and Pommier Y, Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51: 6280-6285, 1991.
15. Salary E, Bertrand R, Kohn KW and Pommier Y, Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81: 1359-1368, 1993.
16. Miller SA, Dykes DD and Polesky HF, A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
17. Liu LF, Rowe TC, Yang L, Tewey KN and Chen GL, Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370, 1984.
18. Yamazaki H, Schneider E, Myers CE and Sinha BK, Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochim Biophys Acta 1226: 89-96, 1994.
19. Chu E, Drake JC, Voeller DM, Zinn S, Jamis-Dow CA, Yeh GC and Allegra CJ, Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143, 1991.
20. Bhalla K, Hindenburg A, Taub RA and Grant S, Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 45: 3657-3662, 1985.
21. Sinha BK and Eliot HM, Etoposide-induced DNA damage in human tumor cells: Requirement for cellular activating factors. Biochim Biophys Acta 1097: 111-116, 1991.
22. Eng WK, McCable FL, Tan KB, Mattern MR, Hoffman GA, Woessner RD, Hertzberg RP and Johnson RK, Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase 1 content. Mol Pharmacol 38: 471-480, 1990.
23. Sinha BK, Mimnaugh EG, Rajagopalan S and Myers CE, Adriamycin activation and oxygen free radical formation in human breast tumor cells: Protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49: 2844-2848, 1989.
24. Dusre L, Rajagopalan S, Eliot HM, Covey JM and Sinha BK, DNA interstrand cross-link and free radical formation in human multidrug resistant tumor cells. Chem Biol Interact 76: 89-99, 1990.
25. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M, Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
26. James JS, Basnakian AG and Miller BJ, In vitro folate deficiency induces deoxynucleotide pool imbalance, apoptosis and mutagenesis in Chinese hamster ovary cells. Cancer Res 54: 5075-5080, 1994.
27. Ayusawa D, Arai H, Wataya Y and Seno T, A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutat Res 200: 221-230, 1988.
28. Canman CE, Tang H-Y, Normolle DP, Lawrence TS and Maybaum J, Variations in patients of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci USA 89: 10474-10478, 1992.
29. Holm C, Covey JM, Kerrigan D and Pommier Y, Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368, 1989.
30. Ryan AJ, Squires S, Strutt HL and Johnson RT, Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double-strand breaks in replicating DNA. Nucleic Acids Res 19: 3295-3300, 1991.
31. Adjei AA, Charron M, Rowinsky EK, Donehower RC, Sebolt-Leopold J and Kaufman SH, Pyrazoloacridine inhibits DNA topoisomerase I and II. Proc Am Assoc Cancer Res 36: 349, 1995.
32. Politi PM, Berg SL, Balis FM, Poplack DG, Allegra CJ and Grem JL, Cytotoxicity and cell-associated levels of pyrazoloacridine in human multidrug resistant tumor cell lines. Proc Am Assoc Cancer Res 33: 524, 1992.
33. Foster BJ, Wiegand RA, LoRusso PM and Baker LH, Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: Guidelines for early clinical trials. Clin Cancer Res 1: 831-837, 1995.
34. LoRusso PM, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valvdivieso M and Baker L, Phase 1 clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1: 1487-1493, 1995.
35. Rowinsky EK, Noe DA, Grochow LB, Sartorius SE, Chen T-L, Lubejko BG, Ettinger D, Bowling KM, Kaufman SH and Donehower RC, Phase I and pharmacokinetic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13: 1975-1984, 1995.
36. Berg SL, Blaney SM, Adamson PC, Arndt C, Mirro J, Blatt J, O'Brien M, Balis RM and Poplack DG, Phase I and pharmacokinetic study of pyrazoloacridine in pediatric patients with advance malignancy. Proc Am Assoc Cancer Res 34: 390, 1993.